CN114732474A - Halloysite-melanin surface codeposition hemostatic bandage and preparation method thereof - Google Patents
Halloysite-melanin surface codeposition hemostatic bandage and preparation method thereof Download PDFInfo
- Publication number
- CN114732474A CN114732474A CN202210484304.4A CN202210484304A CN114732474A CN 114732474 A CN114732474 A CN 114732474A CN 202210484304 A CN202210484304 A CN 202210484304A CN 114732474 A CN114732474 A CN 114732474A
- Authority
- CN
- China
- Prior art keywords
- halloysite
- melanin
- hemostatic bandage
- hemostatic
- natural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title abstract description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 84
- HPTYUNKZVDYXLP-UHFFFAOYSA-N aluminum;trihydroxy(trihydroxysilyloxy)silane;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O[Si](O)(O)O HPTYUNKZVDYXLP-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229910052621 halloysite Inorganic materials 0.000 claims abstract description 44
- 239000002245 particle Substances 0.000 claims abstract description 43
- 239000002071 nanotube Substances 0.000 claims abstract description 40
- 238000005470 impregnation Methods 0.000 claims abstract description 5
- 239000000758 substrate Substances 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- 239000000463 material Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 19
- 210000003746 feather Anatomy 0.000 claims description 13
- 210000004209 hair Anatomy 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 8
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 3
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 239000008367 deionised water Substances 0.000 description 31
- 229910021641 deionized water Inorganic materials 0.000 description 31
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 20
- 238000005406 washing Methods 0.000 description 18
- 239000008363 phosphate buffer Substances 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- 238000001035 drying Methods 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 14
- 108010067770 Endopeptidase K Proteins 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 229910021536 Zeolite Inorganic materials 0.000 description 5
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000010457 zeolite Substances 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 206010051373 Wound haemorrhage Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/132—Tourniquets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
- A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01012—Non-adhesive bandages or dressings characterised by the material being made of natural material, e.g. cellulose-, protein-, collagen-based
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Manufacturing & Machinery (AREA)
- Surgery (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a halloysite-melanin surface codeposition hemostatic bandage and a preparation method thereof. The halloysite-melanin surface codeposition hemostatic bandage is prepared by sequentially codepositing natural melanin particles and halloysite nanotubes on the surface of a hemostatic bandage substrate only through simple impregnation, and the halloysite-melanin surface codeposition hemostatic bandage is simple in preparation process, has synergistic high-efficiency hemostatic performance with the halloysite nanotubes and the natural melanin particles, and has good biological safety.
Description
Technical Field
The invention belongs to the technical field of functional hemostatic materials, and particularly relates to a halloysite-melanin surface codeposition hemostatic bandage and a preparation method thereof.
Background
The development and utilization of safe and efficient hemostatic materials are the key to the success of pre-hospital first aid. The main hemostatic components of the current common hemostatic materials are chitosan, silicon dioxide, zeolite and the like. The chitosan hemostatic material has a porous structure and amino groups, can increase the adhesion of platelets and promote blood components such as red blood cells to aggregate at a wound site to form thrombus (Du, X, Liu, Y, Yan, H, et al, anti-infection and pro-complex hydrogel adhesive for less tissue and close. biomacromolecules 2020,21,1243 and 1253), but the application of the chitosan hemostatic material is limited because the chitosan hemostatic material is difficult to degrade and easily causes in vivo anaphylactic reaction. Mesoporous silica can promote the activation of coagulation factor XII and accelerate coagulation cascade to promote coagulation (Wang, C., Zhou, H., Niu, H., et al, tannic acid-loaded mesoporous silica for rapid homology and antibacterial activity, Biomaterials science.2018,6,3318-3331), but the potential metabolic toxicity and difficulty in cleaning powder particles at wounds limit the application thereof. The zeolite-based hemostatic material can adsorb water in blood at a wound to promote aggregation of platelets and coagulation factors, and at the same time, calcium ions released by the zeolite-based hemostatic material can activate platelets to accelerate the coagulation process (Liang, Y., Xu, C., Liu F., et al., experiment heat input of zeolite in a haemostasis tissue and ACS Applied Materials interface 2019,11,23848 and 23857), but the severe exothermic effect of the zeolite-based hemostatic material can cause secondary injury to the wound. Therefore, there is a need to develop a hemostatic material that combines rapid blood coagulation with biosafety.
Disclosure of Invention
Aiming at the defects of the existing hemostatic material, the invention aims to provide a halloysite-melanin surface codeposition hemostatic bandage and a preparation method thereof.
In order to achieve the technical purpose, the invention adopts the following technical scheme:
a halloysite-melanin surface codeposition hemostatic bandage is prepared by codeposition of natural melanin particles and halloysite nanotubes on the surface of hemostatic bandage base material in sequence.
Further, the mass ratio of the natural melanin particles to the halloysite nanotubes is 0.005-0.1: 1.
further, the natural melanin granules are extracted from at least one of animal hair, feathers, fungi, and bacteria.
Further, the hemostatic bandage base material is selected from one of medical gauze, medical sponge, silk fiber and cotton and linen gauze.
The invention also provides a preparation method of the halloysite-melanin surface codeposition hemostatic bandage, which comprises the following steps:
(1) firstly, immersing a hemostatic bandage substrate in a trihydroxymethyl aminomethane buffer solution, adjusting the pH to 8-9, and performing ultrasonic dispersion pretreatment;
(2) adding the natural melanin particles into the step (1), stirring in a water bath, ultrasonically dispersing, and standing to obtain a hemostatic bandage deposited on the surface of the natural melanin particles;
(3) and (3) finally, placing the hemostasis bandage deposited on the surface of the natural melanin particle in the step (2) in a halloysite nanotube solution, alternately dipping the front side and the back side of a water bath for multiple times, and standing to obtain the halloysite-melanin surface codeposition hemostasis bandage.
Further, in the step (1), the concentration of the tris buffer solution is 8-12mM, and the ultrasonic dispersion time is 0.5-2 h.
Further, in the step (2), the mass concentration of the natural melanin granules is 0.1-1 wt%, the water bath temperature is 45-55 ℃, and the standing time is 12-24 h.
Further, in the step (3), the mass concentration of the halloysite nanotube solution is 10-30 wt%, the water bath temperature is 45-55 ℃, the number of times of alternate impregnation of the front and back surfaces is 3-6, the impregnation time is 1-2h each time, and the standing time is 12-24 h.
The halloysite nanotube can be obtained by carrying out conventional treatment on halloysite raw ore through water washing, ultrasonic stirring, multiple times of centrifugal separation and the like, and the further preferable size is 400-600 nm; the natural melanin granules can be extracted from animal hair, feathers, fungi, bacteria, etc., and can be obtained by, for example, diluting at least one of animal hair, feathers, fungi, and bacteria in a phosphate buffer, subjecting The diluted animal hair, feathers, fungi, and bacteria to enzymolysis or ultrasound, washing with water, centrifuging, and drying, etc. (refer to The emulsification of The biological structures of natural animal Journal of The Royal Society Interface,2018,15,20180045), and a more preferable size is 200 to 400 nm. The treatment means of the halloysite nanotubes and the natural melanin particles in the invention are the conventional processes, and are not described herein again.
Compared with the prior art, the invention has the advantages that:
(1) according to the halloysite-melanin surface codeposition hemostatic bandage, the natural melanin particles and the halloysite nanotubes are sequentially deposited on the surface of the base material, and rich surface polar groups (mainly carboxyl and hydroxyl) of the natural melanin particles can effectively enhance the adhesion effect of the halloysite nanotubes and the surface of the base material, so that the problem of falling-off of hemostatic active components is avoided; the deposited natural melanin particles can promote the adhesion and aggregation of platelets and thrombin protein, the halloysite active component particles distributed on the surface of the hemostatic bandage can fully contact blood components to activate a blood coagulation cascade reaction, and the two generate a synergistic effect to accelerate a blood coagulation process.
(2) The halloysite-melanin surface codeposition hemostatic bandage not only provides attachment and support sites for blood-stopping active component particles, but also can form a physical barrier effect on blood flow at a wound, and has the characteristic of easy bandaging and use.
(3) The halloysite-melanin surface codeposition hemostatic bandage is simple in preparation process, and the halloysite nanotubes and natural melanin particles have synergistic high-efficiency hemostatic performance and good biological safety.
Drawings
FIG. 1 is an SEM image of a conventional Medical gauze bandage (Medical gauze BDs; comparative example 4); among them, the Medical gauze BDs fiber surface is smooth and has strip-shaped folds.
FIG. 2 is an SEM image of halloysite-melanin surface codeposition hemostatic bandages (HNTs-MGs BDs; example 1); wherein, the HNTs-MGs BDs have rough surfaces, and a large amount of halloysite nanotube particles are deposited on the outermost layer of the surface.
FIG. 3 is a bar graph of hemostasis time for different hemostatic materials; wherein: blank control group (NC), halloysite-melanin surface codeposition hemostatic bandage (HNTs-MGs BDs; example 1), halloysite-melanin composite powder (HNTs-MGs; comparative example 3), natural melanin granules (MGs; comparative example 2), halloysite nanotubes (HNTs; comparative example 1), common Medical gauze bandage (Medical gauze BDs; comparative example 4).
Detailed Description
The present invention will be further described with reference to the following specific embodiments and accompanying drawings, which are intended to make the technical features, scheme flows and innovation points of the present invention more clear. It is to be understood that the present embodiments are illustrative only, and that various modifications and changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application.
Example 1
10g of halloysite nanotube raw ore is dissolved in 800mL of deionized water (mass ratio of 1: 80), magnetically stirred for 8 hours and filtered. And (3) suspending the halloysite nanotube obtained by suction filtration in 100mL of deionized water, naturally settling for 10min, and taking supernatant for centrifugal separation at the rotating speed of 8000 rpm. And (3) drying the precipitate obtained by centrifugation in a drying oven at 60 ℃ for 12 hours to obtain the halloysite nanotube with the particle size range of 400-600 nm.
Commercially available feathers or hairlines were washed with acetone 3 times, deionized water 3 times, and cut into pieces. The obtained feathers or hair were added to 40mL of phosphate buffer (pH 6.8), 0.4g of Dithiothreitol (DTT) was added thereto, and the mixture was mixed well under N2Shaking at 37 deg.C for 12h under atmosphere. Add 1mL of 20mg/mL proteinase K and 0.2g DTT and continue shaking for 12 h. Centrifuging at 8000rpm, washing with deionized water for 3 times, and removing supernatant to obtain precipitate. The resulting pellet was mixed with 0.4mL of proteinase K and 32mg of DTT in 16mL of phosphate buffer, resuspended, and shaken for 12 hours. Centrifuging, removing supernatant, adding 6mL of phosphate buffer and 0.12mL of polyethylene glycol octyl phenyl ether, oscillating for 6h, centrifuging, washing with methanol for 3 times and deionized water for 3 times in sequence. The resulting precipitate was suspended with 0.4mL of proteinase K and 32mg of DTT in 16mL of phosphate buffer, and shaken at 37 ℃ for 12 hours, and this operation was repeated 2 times. And after the enzymolysis reaction is completed, standing for 12 hours at 37 ℃, centrifuging, discarding the supernatant, washing for 3 times by using deionized water, and drying at 50 ℃ to obtain natural melanin particles with the particle size range of 200-400 nm.
The purchased medical gauze was immersed in 100mL of 10mM tris buffer solution, the pH was adjusted to 8.5, and sonication was performed for 1 hour. Adding the natural melanin particles into the solution with the concentration of 0.1 wt%, stirring for 24h at the temperature of 50 ℃ in a water bath, and carrying out ultrasonic treatment for 10min at the interval of 3h, wherein the ultrasonic power is 200w, and the frequency is 40 kHz. Standing for 12h at 50 ℃ in a water bath, taking out the medical gauze, and washing the fallen melanin particles with deionized water to obtain the hemostatic gauze deposited on the melanin surface. Deionized water is used for preparing a halloysite nanotube solution with the mass concentration of 20 wt%, ultrasonic dispersion is carried out for 30min, mechanical stirring is carried out for 2h, and the operation is repeated for 3 times to obtain the halloysite nanotube solution with uniform dispersion. The obtained melanin hemostatic gauze was immersed in a halloysite nanotube solution at 50 ℃ in a water bath with the upper side facing the front, and this operation was repeated 3 times with the front turned down with forceps every 1 hour. Then, standing for 12h to ensure that halloysite nanotubes (the mass ratio of the natural melanin particles to the HNTs) are fully deposited on the surface of the gauze. And (3) taking out the gauze, washing the fallen halloysite nanotube particles with deionized water, and drying in an oven at 50 ℃ to obtain the halloysite-melanin surface codeposition hemostatic bandage.
Example 2
30g of halloysite nanotube raw ore is dissolved in 800mL of deionized water (mass ratio of 3: 80), magnetically stirred for 8 hours and filtered. And (3) resuspending the halloysite nanotube obtained by suction filtration in 300mL of deionized water, naturally settling for 10min, and taking supernatant to perform centrifugal separation at the rotating speed of 8000 rpm. And (3) drying the precipitate obtained by centrifugation in an oven at 80 ℃ for 10 hours to obtain the halloysite nanotube with the particle size range of 400-600 nm.
Commercially available feather or hair is taken, washed with acetone for 3 times, washed with deionized water for 3 times, and cut into pieces. The obtained feathers or hair were added to 40mL of phosphate buffer (pH 6.8), 0.4g of Dithiothreitol (DTT) was added thereto, and the mixture was mixed well under N2Shaking at 37 deg.C for 12h under atmosphere. Add 1mL of 20mg/mL proteinase K and 0.2g DTT and continue shaking for 12 h. Centrifuging at 8000rpm, washing with deionized water for 3 times, and removing supernatant to obtain precipitate. The resulting precipitate was combined with 0.4mL proteinase K, 32mg DTT and 16mL phosphorusResuspend and shake in acid buffer for 12 h. Centrifuging, removing supernatant, adding 6mL of phosphate buffer and 0.12mL of polyethylene glycol octyl phenyl ether, oscillating for 6h, centrifuging, washing with methanol for 3 times and deionized water for 3 times in sequence. The resulting precipitate was suspended with 0.4mL of proteinase K and 32mg of DTT in 16mL of phosphate buffer, and shaken at 37 ℃ for 12 hours, and this operation was repeated 2 times. And after the enzymolysis reaction is completed, standing for 12 hours at 37 ℃, centrifuging, discarding the supernatant, washing for 3 times by using deionized water, and drying at 50 ℃ to obtain natural melanin particles with the particle size range of 200-400 nm.
The purchased medical gauze was immersed in 100mL of 12mM tris buffer solution, the pH was adjusted to 8, and sonication was performed for 1 hour. Adding natural melanin granules into the solution with the concentration of 1 wt%, stirring for 24h at the temperature of 50 ℃ in a water bath, and carrying out ultrasonic treatment for 10min at intervals of 2h, wherein the ultrasonic power is 100w, and the frequency is 40 kHz. Standing for 24h at 50 ℃ in a water bath, taking out the medical gauze, and washing the fallen melanin particles with deionized water to obtain the hemostatic gauze deposited on the melanin surface. Deionized water is used for preparing a halloysite nanotube solution with the mass concentration of 10 wt%, ultrasonic dispersion is carried out for 30min, mechanical stirring is carried out for 2h, and the operation is repeated for 3 times to obtain the halloysite nanotube solution with uniform dispersion. The obtained melanin hemostatic gauze was immersed in a halloysite nanotube solution at 50 ℃ in a water bath, with the upward side being the front side, and the front side was turned downward with tweezers every 1h, and this operation was repeated 6 times. Then, standing for 24h to ensure that halloysite nanotubes (the mass ratio of the natural melanin particles to the HNTs) are fully deposited on the surface of the gauze. And (3) taking out the gauze, washing the fallen halloysite nanotube particles with deionized water, and drying in an oven at 48 ℃ to obtain the halloysite-melanin surface codeposition hemostatic bandage.
Comparative example 1
20g of halloysite nanotube raw ore is dissolved in 800mL of deionized water (mass ratio of 1: 40), magnetically stirred for 8 hours and filtered. And (3) suspending the halloysite nanotubes obtained by suction filtration in 100mL of deionized water, naturally settling for 10min, and taking supernatant for centrifugal separation at the rotating speed of 8000 rpm. And (3) drying the precipitate obtained by centrifugation in an oven at 60 ℃ for 12 hours to obtain the halloysite nanotube with the particle size range of 400-600 nm.
Comparative example 2
Commercially available feather or hair is taken, washed with acetone for 3 times, washed with deionized water for 3 times, and cut into pieces. The obtained feathers or hairs were added to 40mL of phosphate buffer (pH 6.8), 0.4g of Dithiothreitol (DTT) was added thereto, and the mixture was mixed well under N2Shaking at 37 deg.C for 12h under atmosphere. Add 1mL of 20mg/mL proteinase K and 0.2g DTT and continue shaking for 12 h. Centrifuging at 8000rpm, washing with deionized water for 3 times, and removing supernatant to obtain precipitate. The resulting pellet was mixed with 0.4mL proteinase K and 32mg DTT in 16mL phosphate buffer, resuspended, and shaken for 12 h. Centrifuging, removing supernatant, adding 6mL of phosphate buffer and 0.12mL of polyethylene glycol octyl phenyl ether, oscillating for 6h, centrifuging, washing with methanol for 3 times and deionized water for 3 times in sequence. The resulting precipitate was suspended with 0.4mL of proteinase K and 32mg of DTT in 16mL of phosphate buffer, and shaken at 37 ℃ for 12 hours, and this operation was repeated 2 times. And after the enzymolysis reaction is completed, standing for 12 hours at 37 ℃, centrifuging, discarding the supernatant, washing for 3 times by using deionized water, and drying at 50 ℃ to obtain natural melanin particles with the particle size range of 200-400 nm.
Comparative example 3
10g of halloysite nanotube raw ore is dissolved in 800mL of deionized water (mass ratio of 1: 80), magnetically stirred for 8 hours and filtered. And (3) suspending the halloysite nanotubes obtained by suction filtration in 100mL of deionized water, naturally settling for 10min, and taking supernatant for centrifugal separation at the rotating speed of 8000 rpm. And (3) drying the precipitate obtained by centrifugation in a drying oven at 60 ℃ for 12 hours to obtain the halloysite nanotube with the particle size range of 400-600 nm.
Commercially available feather or hair is taken, washed with acetone for 3 times, washed with deionized water for 3 times, and cut into pieces. The obtained feathers or hair were added to 40mL of phosphate buffer (pH 6.8), 0.4g of Dithiothreitol (DTT) was added thereto, and the mixture was mixed well under N2Shaking at 37 deg.C for 12h under atmosphere. Add 1mL of 20mg/mL proteinase K and 0.2g DTT and continue shaking for 12 h. Centrifuging at 8000rpm, washing with deionized water for 3 times, and removing supernatant to obtain precipitate. The resulting precipitate was mixed with 0.4mL eggThe protease K and 32mg DTT were added to 16mL of phosphate buffer, resuspended, and shaken for 12 h. Centrifuging, removing supernatant, adding 6mL of phosphate buffer and 0.12mL of polyethylene glycol octyl phenyl ether, oscillating for 6h, centrifuging, washing with methanol for 3 times and deionized water for 3 times in sequence. The resulting precipitate was suspended with 0.4mL of proteinase K and 32mg of DTT in 16mL of phosphate buffer, and shaken at 37 ℃ for 12 hours, and this operation was repeated 2 times. And after the enzymolysis reaction is completed, standing for 12 hours at 37 ℃, centrifuging, discarding the supernatant, washing for 3 times by using deionized water, and drying at 50 ℃ to obtain natural melanin particles with the particle size range of 200-400 nm.
50mL of 12mM Tris buffer solution was prepared, pH was adjusted to 8, and sonication was performed for 1 h. Adding 100mg natural melanin granules into the solution, magnetically stirring for 2 h-ultrasonic dispersion for 10min at the temperature of 50 ℃ in a water bath, and repeating the operation for 3 times, wherein the ultrasonic power is 100w and the frequency is 40 kHz. 20g of HNTs nanoparticles were dissolved in 50mL of deionized water and stirred in a water bath at 50 ℃ for 12 h. Mixing the natural melanin particle solution and the HNTs solution in equal volume (the mass ratio of the natural melanin particles to the HNTs is 0.5%), performing ultrasonic dispersion for 10 min-magnetically stirring for 2h in a water bath at 50 ℃, and repeating the operation for 6 times, wherein the ultrasonic power is 100w, and the frequency is 40 kHz. Standing the obtained HNTs-melanin composite hemostatic powder for 24h, and drying in an oven at 50 ℃ to obtain the halloysite-melanin composite hemostatic powder.
Comparative example 4
A sample of a control group of conventional Medical gauze bandages (Medical gauze BDs) was prepared by taking commercially available conventional Medical gauze bandages, sterilizing the gauze bandages by ultraviolet irradiation for 2 hours, and cutting the gauze bandages into small disks having a diameter of 1.2cm while operating in an aseptic environment.
The hemostatic performance of the hemostatic material is evaluated by a mouse liver wound bleeding model, obvious wound bleeding is formed on the surface of the mouse liver by using an operating knife, and the hemostatic performance is evaluated by applying the same amount of the material prepared in example 1 and the materials prepared in comparative examples 1-3 to the surface of the wound. As shown in fig. 3, the halloysite-melanin composite powder prepared in comparative example 3 has significant statistical advantages in hemostatic time, compared to Halloysite Nanotubes (HNTs) of comparative example 1 and natural melanin particles (MGs) of comparative example 2, indicating that the halloysite and natural melanin composite powder can synergistically improve hemostatic performance; compared with the halloysite-melanin composite powder (HNTs-MGs) of the comparative example 3, the halloysite nanotube-melanin surface codeposition hemostatic bandage (HNTs-MGs BDs) of the example 1 has shorter hemostatic time, and has the advantages of convenient dressing and easy operation; compared with a blank control group (NC) and a common Medical gauze bandage group (Medical gauze BDs; comparative example 4), the HNTs-MGs BDs present remarkable hemostatic performance advantages. In conclusion, the halloysite-melanin surface codeposition hemostatic bandage has good usability and synergistic and efficient hemostatic performance.
Claims (8)
1. A halloysite-melanin surface codeposition hemostatic bandage is characterized in that: the halloysite-melanin surface codeposition hemostatic bandage is formed by sequentially codepositing natural melanin particles and halloysite nanotubes on the surface of a hemostatic bandage base material.
2. The halloysite-melanin surface codeposition hemostatic bandage of claim 1, wherein: the mass ratio of the natural melanin particles to the halloysite nanotubes is 0.005-0.1: 1.
3. the halloysite-melanin surface co-deposition hemostatic bandage of claim 1, wherein: the natural melanin granules are extracted from at least one of animal hair, feathers, fungi, and bacteria.
4. The halloysite-melanin surface co-deposition hemostatic bandage of claim 1, wherein: the hemostatic bandage base material is selected from one of medical gauze, medical sponge, silk fiber and cotton and linen gauze.
5. A method of making a halloysite-melanin surface co-deposition hemostatic bandage as claimed in any one of claims 1 to 4, comprising the steps of:
(1) firstly, immersing a hemostatic bandage substrate in a trihydroxymethyl aminomethane buffer solution, adjusting the pH to 8-9, and performing ultrasonic dispersion pretreatment;
(2) adding the natural melanin particles into the step (1), stirring in a water bath, ultrasonically dispersing, and standing to obtain a hemostatic bandage deposited on the surface of the natural melanin particles;
(3) and (3) finally, placing the hemostatic bandage deposited on the surface of the natural melanin particles in the step (2) into a halloysite nanotube solution, alternately dipping the front side and the back side of the water bath for multiple times, and standing to obtain the halloysite-melanin surface codeposition hemostatic bandage.
6. The method of claim 5, wherein: in the step (1), the concentration of the trihydroxymethyl aminomethane buffer solution is 8-12mM, and the ultrasonic dispersion time is 0.5-2 h.
7. The method of claim 5, wherein: in the step (2), the mass concentration of the natural melanin granules is 0.01-1 wt%, the water bath temperature is 45-55 ℃, and the standing time is 12-24 h.
8. The method of claim 5, wherein: in the step (3), the mass concentration of the halloysite nanotube solution is 10-30 wt%, the water bath temperature is 45-55 ℃, the number of times of alternate impregnation of the front and back surfaces is 3-6, the impregnation time is 1-2h each time, and the standing time is 12-24 h.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210484304.4A CN114732474A (en) | 2022-05-06 | 2022-05-06 | Halloysite-melanin surface codeposition hemostatic bandage and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210484304.4A CN114732474A (en) | 2022-05-06 | 2022-05-06 | Halloysite-melanin surface codeposition hemostatic bandage and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114732474A true CN114732474A (en) | 2022-07-12 |
Family
ID=82285867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210484304.4A Pending CN114732474A (en) | 2022-05-06 | 2022-05-06 | Halloysite-melanin surface codeposition hemostatic bandage and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114732474A (en) |
-
2022
- 2022-05-06 CN CN202210484304.4A patent/CN114732474A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106729927B (en) | Modified bioactive glass/polyacrylamide/oxidized sodium alginate hydrogel dressing and preparation method thereof | |
WO2019242390A1 (en) | Molecular sieve/fiber composite material and preparation method therefor | |
CN103834050A (en) | Method for preparing gelatin/nano-silver/chitosan derivative composite film | |
CN110464868B (en) | Silicate clay modified hemostatic material and preparation method thereof | |
CN110141677B (en) | Local acute hemostasis absorbable material and preparation method thereof | |
JP7503814B2 (en) | Hemostatic composite and method for producing same | |
CN112791223B (en) | Antibacterial chitosan-based hemostatic patch | |
CN110665048A (en) | Kaolin-modified hemostatic material and preparation method thereof | |
CN103721247A (en) | Collagen-based composite hemostasis powder and preparation method thereof | |
CN107261199B (en) | Preparation method of zeolite-containing hemostatic gel dressing | |
CN114732474A (en) | Halloysite-melanin surface codeposition hemostatic bandage and preparation method thereof | |
WO2021027006A1 (en) | Novel degradable hemostatic material and preparation method therefor | |
KR102645889B1 (en) | Hemostatic fabric containing trypsin and method for manufacturing the same | |
CN112933287B (en) | Grafted polyalkyl chitosan coated bioactive glass powder and preparation method and application thereof | |
CN114712549B (en) | Montmorillonite-melanin composite hemostatic powder and preparation method and application thereof | |
CN110975001B (en) | Chitosan-cellulose composite hemostatic sponge and preparation method and application thereof | |
WO2023165052A1 (en) | Directional driving hemostatic microsphere with puncture function and preparation method thereof | |
CN114788890A (en) | Attapulgite-melanin hemostatic gel and preparation method and application thereof | |
CN114209875B (en) | Bioactive glass nano composite particles with antibacterial effect and high-efficiency hemostatic membrane-like structure camouflage and preparation method thereof | |
CN115671374A (en) | Silk fibroin-based hemostatic adhesive powder and preparation method thereof | |
CN114788889A (en) | Kaolinite-melanin composite hemostatic fiber material and preparation method and application thereof | |
CN111744052B (en) | Preparation method of spongy hemostatic material | |
CN108310443B (en) | Efficient and environment-friendly tourniquet and preparation method thereof | |
CN107661536B (en) | Hierarchical pore composite hemostatic containing molecular sieve and preparation method and application thereof | |
CN102167847B (en) | Chitosan and sulfating grifolan mixed gel freeze-dried sponge, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |